Interventional, Open-label, Flexible-dose Extension Study of Aripiprazole Once-monthly in Patients With Schizophrenia
Phase of Trial: Phase III
Latest Information Update: 21 Mar 2017
At a glance
- Drugs Aripiprazole (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Registrational
- Sponsors Lundbeck A/S
- 11 May 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 16 Nov 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2012-003239-47 ).
- 16 Oct 2013 New trial record